Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30235588 | 0.84 | MAPK1 (0.49) | MAPK1NAMPTBCHEDDB1CRBN | |
| SCHEMBL18325444 | 0.84 | MAPK1 (0.49) | MAPK1NAMPTBCHEDDB1CRBN | |
| SCHEMBL29676965 | 0.82 | MAPK1 (0.64) | MAPK1NAMPTDDB1CRBNESR2 | |
| SCHEMBL5183098 | 0.82 | MAPK1 (0.64) | MAPK1NAMPTDDB1CRBNESR2 | |
| SCHEMBL21257672 | 0.81 | HRH1 (0.46) | MAPK1NAMPTDDB1CRBNHDAC1 | |
| SCHEMBL84344 | 0.81 | USP2 (0.46) | MAPK1DDB1CRBNESR2NR1H2 | |
| SCHEMBL3760649 | 0.80 | DPP4 (0.46) | BCHEDPP4 | |
| SCHEMBL21505062 | 0.80 | MAPK1 (0.59) | MAPK1NAMPTBCHEESR2NR1H2 | |
| SCHEMBL31033144 | 0.79 | MAPK1 (0.45) | MAPK1NAMPTHDAC1HDAC6DPP4 | |
| SCHEMBL3427103 | 0.78 | DPP4 (0.51) | MAPK1NAMPTHDAC1HDAC6DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2250157-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Panacea Biotec Limited (IN) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | MAPK1 2715/4885NAMPT 425/4885BCHE 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.